VolitionRx Limited (NYSEAM:VNRX) is looking for acquisitions. VolitionRx announced that it has commenced an underwritten public offering of shares of its common stock. Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7471 USD | -2.97% | -14.86% | +4.20% |
May. 14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.20% | 61.88M | |
-31.06% | 9.41B | |
+27.31% | 2.9B | |
-14.31% | 2.16B | |
-18.94% | 1.7B | |
+73.13% | 1.51B | |
+30.25% | 814M | |
-1.97% | 760M | |
-26.73% | 529M | |
+5.17% | 312M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- VolitionRx Seeks Acquisitions